Company intelligence / Profile preview

InVivo Therapeutics Holdings Corp.

Cambridge, Massachusetts, United Statessec.gov ↗

Ownership: Public · NVIV
Employees: ~6
Development stage: Phase 1

Overview

The company is developing a Neuro-Spinal Scaffold implant for treatment of spinal cord injuries. The scaffold is made of biocompatible and bioresorbable polymers including Poly lactic-co-glycolic acid and Poly-L-Lysine.

Therapeutic areas: Neurology
Modalities: Biopolymer scaffolding devices
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Neuro-Spinal Scaffold

Phase 1

Indications: Acute spinal cord injury

Financials

Market cap: $995.9K
Total revenue: $0
Enterprise value: $-7.6M

Beyond the preview

Go deeper on InVivo Therapeutics Holdings Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InVivo Therapeutics Holdings Corp..

Explore the full profile